Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement von Stangier, Joachim, Eriksson, Bengt I., Dahl, Ola E., Ahnfelt, Lennart, Nehmiz, Gerhard, Stähle, Hildegard, Rathgen, Karin, Svärd, Robbyna

Volltext

Joint bayesian network meta-analysis for event counts and hazards – comparison of methods and implementations von Schmidt, H, Nehmiz, G

Volltext

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I von Eriksson, B. I., Dahl, O. E., Ahnfelt, L., Kälebo, P., Stangier, J., Nehmiz, G., Hermansson, K., Kohlbrenner, V.

Volltext

1236 MECHANISMS OF ISOLATED UNCONJUGATED HYPERBILIRUBINEMIA INDUCED BY THE HCV NS3/4A PROTEASE INHIBITOR BI201335 von Sane, R, Podila, L, Mathur, A, Mease, K, Taub, M, Huang, Q, Elgadi, M, Nehmiz, G, Steinmann, G

Volltext

1185 CHARACTERIZATION OF HCV NS3 VARIANTS THAT EMERGED DURING VIROLOGIC BREAKTHROUGH AND RELAPSE FROM BI 201335 PHASE II SILEN-C2 STUDY IN PEGIFN/RBV TREATMENT-EXPERIENCED PATIENTS von Kukolj, G, Bethell, R, Cartier, M, Cote-Martin, A, Lagace, L, Marquis, M, Triki, I, Sulkowski, M, Asselah, T, Lalezari, J, Ferenci, P, Bocher, W.O, Datsenko, Y, Nehmiz, G, Scherer, J, Steinmann, G, Stern, J.O

Volltext

Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study) von Ezekowitz, Michael D., MD, PhD, Reilly, Paul A., PhD, Nehmiz, Gerhard, PhD, Simmers, Timothy A., MD, Nagarakanti, Rangadham, MD, Parcham-Azad, Kambiz, MD, Pedersen, K. Erik, MD, Lionetti, Dominick A., MA, Stangier, Joachim, PhD, Wallentin, Lars, MD, PhD

Volltext

PRM142 - Joint bayesian network meta-analysis for event counts and hazards – comparison of methods and implementations von Schmidt, H., Nehmiz, G.

Volltext

60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 H... von Sulkowski, M.S, Ceasu, E, Asselah, T, Caruntu, F.A, Lalezari, J, Ferenci, P, Streinu-Cercel, A, Fainboim, H, Tanno, H, Preotescu, L, Leggett, B, Bessone, F, Mauss, S, Stern, J.O, Häfner, C, Datsenko, Y, Nehmiz, G, Böcher, W, Steinmann, G

Volltext

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients von Hinrichsen, Holger, Benhamou, Yves, Wedemeyer, Heiner, Reiser, Markus, Sentjens, Roel E., Calleja, José L., Forns, Xavier, Erhardt, Andreas, Crönlein, Jens, Chaves, Ricardo L., Yong, Chan-Loi, Nehmiz, Gerhard, Steinmann, Gerhard G.

Volltext

Effect of hospitalisation on liver enzymes in healthy subjects von NARJES, H, NEHMIZ, G

Volltext

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C von REISER, Markus, HINRICHSEN, Holger, BENHAMOU, Yves, REESINK, Henk W, WEDEMEYER, Heiner, AVENDANO, Cristina, RIBA, Neus, YONG, Chan-Loi, NEHMIZ, Gerhard, STEINMANN, Gerhard G

Volltext

1054 SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BI 207127, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C von Larrey, D, Benhamou, Y, Lohse, A.W, Trepo, C, Moelleken, C, Bronowicki, J.-P, Arastéh, K, Bourlière, M, Heim, M, Enríquez, J, Erhardt, A, Zarski, J.-P, Wiest, R, Gerlach, T, Wedemeyer, H, Berg, T, Stern, J, Wu, K, Abdallah, N, Nehmiz, G, Boecher, W, Steffgen, J

Volltext

An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary u... von Eriksson, Bengt I, Mikuska, Zsolt, Feuring, Martin, Amiral, Jean, Haertter, Sebastian, Stangier, Joachim, Nehmiz, Gerhard, Weitz, Jeffrey I

Volltext

[586] SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BILB1941, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C von Erhardt, A, Wedemeyer, H, Benhamou, Y, Moellekens, C, Forns, X, Pol, S, Calleja, J.L, Ross, S, Spangenberg, H.C, Garcia-Samaniego, J, Fuchs, M, Enriquez, J, Wiegand, T, Stern, J, Wu, K, Nehmiz, G, Steffgen, J

Volltext

Pharmacokinetics and tolerability of meloxicam after i.m. administration von NARJES, H., TÜRCK, D., BUSCH, U., HEINZEL, G., NEHMIZ, G.

Volltext

Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation A phase II study von Akkerhuis, K. M., Neuhaus, K.-L., Wilcox, R. G., Vahanian, A., Boland, J.-L., Hoffmann, J., Baardman, T., Nehmiz, G., Roth, U., Klootwijk, A. P. J., Deckers, J. W., Simoons, M. L.

Volltext

Effect of Food on the Pharmacokinetics of Meloxicam after Oral Administration von Türck, D., Busch, U., Heinzel, G., Narjes, H., Nehmiz, G.

Volltext

Dipyridamole alone or combined with low‐dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo [see comments] von Muller, TH, Su, CA, Weisenberger, H, Brickl, R, Nehmiz, G, Eisert, WG

Volltext

Long-term efficacy and safety of Pimobendan in moderate heart failure: A double-blind parallel 6-month comparison with enalapril von REMME, W. J., KRAYENBÜHL, H. P., BAUMANN, G., FRICK, M. H., HAEHL, M., NEHMIZ, G., BAIKER, W.

Volltext

Meloxicam pharmacokinetics in renal impairment von BOULTON-JONES, J. M, GEDDES, C. G, HEINZEL, G, TÜRCK, D, NEHMIZ, G, BEVIS, P. J. R

Volltext